Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Cutler

Showing results (141-150 of 217) with videos related to

Pageof 22
Sort By:
Mental Health Services Research|March 21, 2001
Psychiatric hospitalizations, arrests, emergency room visits, and homelessness of clients with serious and persistent mental illness: findings from a randomized trial of two ACT programs vs. usual careG N Clarke, H A Herinckx, R F Kinney, et al.
European Journal of Clinical Pharmacology|April 6, 2012
Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarinTeddy Kosoglou, Yali Zhu, Fengjuan Xuan, et al.
British Journal of Clinical Pharmacology|March 12, 1999
Pharmacokinetics of flutamide in patients with renal insufficiencyS Anjum, S K Swan, L J Lambrecht, et al.
Clinical Pharmacology and Therapeutics|August 1, 1997
Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteersR D Huhn, E Radwanski, J Gallo, et al.
Current Medical Research and Opinion|August 25, 2004
Pharmacodynamic interaction between ezetimibe and rosuvastatinTeddy Kosoglou, Paul Statkevich, Bo Yang, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Effect of Food, Antacid, and Age on the Pharmacokinetics of the Oral Thrombin Receptor Antagonist Vorapaxar (SCH 530348) in Healthy VolunteersTeddy Kosoglou, Larisa Reyderman, Jack Tseng, et al.
New Directions for Mental Health Services|January 1, 1989
The evolution of Oregon's Public Psychiatry Training ProgramJ D Bloom, D L Cutler, L R Faulkner, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazoneTeddy Kosoglou, Bharath Kumar, Paul Statkevich, et al.
Journal of Clinical Pharmacology|February 22, 2013
The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxarTeddy Kosoglou, Paul Statkevich, Bharath Kumar, et al.
Journal of Clinical Pharmacology|October 12, 1999
Disposition of recombinant human interleukin-10 in subjects with various degrees of renal functionS R Andersen, L J Lambrecht, S K Swan, et al.
Pageof 22

Showing results (141-150 of 217) with videos related to

Sort By:
Pageof 22
Mental Health Services Research|March 21, 2001
Psychiatric hospitalizations, arrests, emergency room visits, and homelessness of clients with serious and persistent mental illness: findings from a randomized trial of two ACT programs vs. usual careG N Clarke, H A Herinckx, R F Kinney, et al.
European Journal of Clinical Pharmacology|April 6, 2012
Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarinTeddy Kosoglou, Yali Zhu, Fengjuan Xuan, et al.
British Journal of Clinical Pharmacology|March 12, 1999
Pharmacokinetics of flutamide in patients with renal insufficiencyS Anjum, S K Swan, L J Lambrecht, et al.
Clinical Pharmacology and Therapeutics|August 1, 1997
Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteersR D Huhn, E Radwanski, J Gallo, et al.
Current Medical Research and Opinion|August 25, 2004
Pharmacodynamic interaction between ezetimibe and rosuvastatinTeddy Kosoglou, Paul Statkevich, Bo Yang, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Effect of Food, Antacid, and Age on the Pharmacokinetics of the Oral Thrombin Receptor Antagonist Vorapaxar (SCH 530348) in Healthy VolunteersTeddy Kosoglou, Larisa Reyderman, Jack Tseng, et al.
New Directions for Mental Health Services|January 1, 1989
The evolution of Oregon's Public Psychiatry Training ProgramJ D Bloom, D L Cutler, L R Faulkner, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazoneTeddy Kosoglou, Bharath Kumar, Paul Statkevich, et al.
Journal of Clinical Pharmacology|February 22, 2013
The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxarTeddy Kosoglou, Paul Statkevich, Bharath Kumar, et al.
Journal of Clinical Pharmacology|October 12, 1999
Disposition of recombinant human interleukin-10 in subjects with various degrees of renal functionS R Andersen, L J Lambrecht, S K Swan, et al.
Pageof 22